Morgan Stanley Maintains Overweight on Alpine Immune Sciences, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Alpine Immune Sciences (NASDAQ:ALPN) and raised the price target from $17 to $30.
November 03, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Alpine Immune Sciences and raised the price target from $17 to $30.
The news of Morgan Stanley maintaining an Overweight rating and raising the price target for Alpine Immune Sciences is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100